CCN5 Composition for Reversing Retinal Pigment Epithelial Fibrosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for fibrotic deformation of retinal pigment epithelial cells, which cause retinal diseases such as proliferative vitreoretinopathy, diabetic retinopathy, and age-related macular degeneration, are inadequate, leading to irreversible vision loss.

Innovation Solution

A pharmaceutical composition comprising CCN5, a CCN5-encoding polynucleotide, or a recombinant virus containing the polynucleotide, is used to prevent or treat retinal diseases by restoring the morphological and functional damage of retinal pigment epithelial cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments are used for fibrotic deformation of retinal pigment epithelial cells, then some therapeutic effect is achieved, but the treatment is inadequate and leads to irreversible vision loss

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidirreversible vision loss

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by introducing CCN5 protein or its encoding nucleic acid to alter the biological state of retinal pigment epithelial cells. This changes the cellular parameters (morphology, function) to reverse fibrotic deformation and prevent vision loss, moving from an inadequate treatment state to an effective restoration state.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If fibrotic deformation of retinal pigment epithelial cells progresses, then the disease state worsens, but early detection and treatment opportunities are lost

Engineering Contradiction:

Improvedisease detection and treatment timingVSAvoidtime for effective intervention

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent employs preliminary action by providing tools for early detection of fibrotic deformation through markers and imaging techniques. This allows intervention before the disease progresses to irreversible stages, capturing the optimal treatment window before time is lost.

Inventive Principle:

Principle #10Preliminary action

3Reliability

If retinal pigment epithelial cells undergo fibrotic deformation, then cellular function is impaired, but restoration to normal state becomes difficult

Engineering Contradiction:

Improvecellular function restorationVSAvoiddifficulty of reversing deformation

Core Design Contradiction:

ReliabilityVSEase of repair

Solution Approach 1:

The patent converts the harmful fibrotic deformation process into a beneficial restoration process by using CCN5 to reverse the deformation. The same cellular pathways involved in fibrotic transformation are leveraged in reverse to restore normal epithelial cell morphology and function, turning the harmful deformation process into a therapeutic opportunity.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS12377130B2Pharmaceutical composition comprising CCN5 as active ingredient, for preventing or treating retinal diseases

Publication Date: 2025.08.05 OLIVES BIOTHERAPEUTICS INC

AI summary

A pharmaceutical composition containing a CCN5 or a fragment thereof, a nucleic acid encoding the CCN5, a vector containing the nucleic acid, or a recombinant cell containing the nucleic acid or the vector, as an active ingredient and its use in preventing or treating retinal diseases are disclosed. The CCN5 prevents fibrotic changes, caused by TGF-β, EEF, or anti-VEGF drugs, in retinal pigment epithelial cells. In addition, CCN5 recuperates the morphological or functional damage, caused by fibrotic changes, of retinal pigment epithelial cells to the level of normal cells. Therefore, the composition containing CCN5 as an active ingredient can be advantageously utilized for preventing or treating retinal diseases.